Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191282
Status:
COMPLETED
Last Update Posted:
2011-01-20
First Post:
2005-09-12
Brief Title:
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes HEART2D
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IONM
Brief Summary:
The primary objective was to demonstrate a difference between two insulin strategies one targeting postprandial PP hyperglycemia and the other targeting fasting and interprandial hyperglycemia on time until the first combined adjudicated cardiovascular CV event primary outcome defined as CV death nonfatal myocardial infarction MI nonfatal stroke coronary revascularization or hospitalized acute coronary syndrome
Detailed Description:
The purpose of this study is to evaluate the effect of two different treatment strategies on CV outcomes in patients with type 2 diabetes while aiming to achieve and maintain HbA1c 70 in both groups Only patients who have recently experienced an acute MI will be considered for participation in this trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F3Z-MC-IONM | OTHER | Eli Lilly and Company | None |